To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer is a phase 2/3 interventional study registered as NCT06504732, led by SUNHO（China）BioPharmaceutical CO., and recruiting on the registry. Official title: A Phase II/III Clinical Study Evaluating IAH0968 in Combination or Not in Combination With the CAPEOX Regimen in HER2-expressing Advanced/Metastatic Solid Tumours and Gastric Cancer. Planned enrolment is 574 participants (estimated). The study started in 2024-08-15 and primary completion is expected in 2028-07. No results have been posted on ClinicalTrials.gov.